Advertisement

Tumor Biology

, Volume 37, Issue 5, pp 6125–6133 | Cite as

Decreased expression of BRCA1-associated protein 1 predicts unfavorable survival in gastric adenocarcinoma

  • Shumei Yan
  • Fan He
  • Rongzhen Luo
  • Huini Wu
  • Mayan Huang
  • Chunyu Huang
  • Yong Li
  • Zhiwei Zhou
Original Article

Abstract

BRCA1-associated protein 1 (BAP1) has been reported as a novel tumor suppressor, while in gastric adenocarcinoma, the function of this protein was still await to be uncovered. Based on a large group of patients with gastric adenocarcinoma, our study aimed to have a further understanding about the correlation of BAP1 expression and patients’ clinical outcomes. We performed quantitative PCR and Western blot to examine BAP1 expression in 38 cases of gastric adenocarcinoma samples and adjacent non-cancerous tissues. Immunochemistry was used to evaluate BAP1 expression in a large cohort of 474 paraffin-embedded specimens. The clinical and prognostic significance of BAP1 expression was statistically analyzed. Postoperative survival between groups was using Kaplan-Meier analysis. BAP1 was overexpressed in paracancerous normal mucosa compared with gastric cancer. Decreased BAP1 expression was associated with higher histologic grade (P = 0.044), tumor infiltration (P < 0.001), metastasis status (P = 0.023), and TNM stage (P < 0.001). Patients with low expression of BAP1 had shorter overall survival compared with those with high expression (P < 0.001). Patients’ survival in stage N0 could be stratified by the expression of BAP1. Multivariate analysis showed that in gastric adenocarcinoma, BAP1 expressing level was an independent prognostic factor (RR = 0.575, P < 0.001). Decreased expression of BAP1 suggests pessimistic prognosis for gastric adenocarcinoma patients. Further studies are warranted.

Keywords

BAP1 Gastric adenocarcinoma Prognosis 

Abbreviations

BAP1

BRCA1-associated protein 1

TNM

Tumor-node-metastasis

IHC

Immunohistochemistry

RT-PCR

Reverse transcription polymerase chain reaction

WB

Western blot

Notes

Acknowledgments

This work was worked supported by the National Natural Science Foundation of China (No. 81172565 and No. 81202135).

Conflicts of interest

None

Supplementary material

13277_2015_3983_Fig5_ESM.jpg (24 mb)
Supplementary Figure 1

OS and FP curves for 593 gastric adenocarcinoma patients according to their BAP1 expression status (output from online Kaplan Meier plotter database). A. OS curves: patients with low (n=296) and high (n=297) expression levels of BAP1 respectively. B. FP curves: the first time when tumor progression was detected among patients with low and high expression levels of BAP1 respectively (JPEG 23.9 MB)

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Gulubova M, Manolova I, Kyurkchiev D, Julianov A, Altunkova I. Decrease in intrahepatic cd56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. APMIS. 2009;117:870–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Iwasa S, Yanagawa T, Fan J, Katoh R. Expression of cxcr4 and its ligand sdf-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis. Anticancer Res. 2009;29:4751–8.PubMedGoogle Scholar
  5. 5.
    Mrena J, Wiksten JP, Kokkola A, Nordling S, Ristimaki A, Haglund C. Cox-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol. 2010;31:1–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Tamura Y, Higashi M, Kitamoto S, Yokoyama S, Osako M, Horinouchi M, et al. Muc4 and muc1 expression in adenocarcinoma of the stomach correlates with vessel invasion and lymph node metastasis: an immunohistochemical study of early gastric cancer. PLoS One. 2012;7, e49251.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17:2693–701.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Song IS, Ha GH, Kim JM, Jeong SY, Lee HC, Kim YS, et al. Human znf312b oncogene is regulated by sp1 binding to its promoter region through DNA demethylation and histone acetylation in gastric cancer. Int J Cancer. 2011;129:2124–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, Gygi SP, et al. Abraxas and rap80 form a brca1 protein complex required for the DNA damage response. Science. 2007;316:1194–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent mutation of arid1a in molecular subtypes of gastric cancer. Nat Genet. 2011;43:1219–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase bap1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43:668–72.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of bap1 in metastasizing uveal melanomas. Science. 2010;330:1410–3.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, et al. Bap1: a novel ubiquitin hydrolase which binds to the brca1 ring finger and enhances brca1-mediated cell growth suppression. Oncogene. 1998;16:1097–112.CrossRefPubMedGoogle Scholar
  14. 14.
    Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A. The deubiquitinating enzyme bap1 regulates cell growth via interaction with hcf-1. J Biol Chem. 2009;284:34179–88.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone h2a deubiquitinase activity of the polycomb repressive complex pr-dub. Nature. 2010;465:243–7.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Stokes MP, Rush J, Macneill J, Ren JM, Sprott K, Nardone J, et al. Profiling of uv-induced atm/atr signaling pathways. Proc Natl Acad Sci U S A. 2007;104:19855–60.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, et al. Brca1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008;68:6953–62.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Guenard F, Labrie Y, Ouellette G, Beauparlant CJ, Durocher F, BRCAs I. Genetic sequence variations of brca1-interacting genes aurka, bap1, bard1 and dhx9 in french canadian families with high risk of breast cancer. J Hum Genet 2009;54:152–161.Google Scholar
  19. 19.
    Coupier I, Cousin PY, Hughes D, Legoix-Ne P, Trehin A, Sinilnikova OM, et al. Bap1 and breast cancer risk. Fam Cancer. 2005;4:273–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S, et al. Bap1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44:751–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline bap1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022–5.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wang W, Lv L, Pan K, Zhang Y, Zhao JJ, Chen JG, et al. Reduced expression of transcription factor ap-2alpha is associated with gastric adenocarcinoma prognosis. PLoS One. 2011;6, e24897.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    He F, Wu HN, Cai MY, Li CP, Zhang X, Wan Q, et al. Inhibition of ovarian cancer cell proliferation by pien tze huang via the akt-mtor pathway. Oncol Lett. 2014;7:2047–52.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Fan LH, Tang LN, Yue L, Yang Y, Gao ZL, Shen Z. Bap1 is a good prognostic factor in advanced non-small cell lung cancer. Clin Invest Med. 2012;35:E182–189.PubMedGoogle Scholar
  25. 25.
    Tang J, Xi S, Wang G, Wang B, Yan S, Wu Y, et al. Prognostic significance of brca1-associated protein 1 in colorectal cancer. Med Oncol. 2013;30:541.CrossRefPubMedGoogle Scholar
  26. 26.
    Angeloni D. Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease. Brief Funct Genomic Proteomic. 2007;6:19–39.CrossRefPubMedGoogle Scholar
  27. 27.
    Tyagi S, Chabes AL, Wysocka J, Herr W. E2f activation of s phase promoters via association with hcf-1 and the mll family of histone h3k4 methyltransferases. Mol Cell. 2007;27:107–19.CrossRefPubMedGoogle Scholar
  28. 28.
    Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, et al. Loss of the tumor suppressor bap1 causes myeloid transformation. Science. 2012;337:1541–6.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Misaghi S, Ottosen S, Izrael-Tomasevic A, Arnott D, Lamkanfi M, Lee J, et al. Association of c-terminal ubiquitin hydrolase brca1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol. 2009;29:2181–92.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009;138:389–403.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Yu H, Mashtalir N, Daou S, Hammond-Martel I, Ross J, Sui G, et al. The ubiquitin carboxyl hydrolase bap1 forms a ternary complex with yy1 and hcf-1 and is a critical regulator of gene expression. Mol Cell Biol. 2010;30:5071–85.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Alatengbaolide, Lin D, Li Y, Xu H, Chen J, Wang B, et al. Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (r0) regardless of the examined number of lymph nodes. Am J Clin Oncol. 2013;36:325–30.CrossRefPubMedGoogle Scholar
  33. 33.
    Pacelli F, Cusumano G, Rosa F, Marrelli D, Dicosmo M, Cipollari C, et al. Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. JAMA Surg. 2013;148:353–60.CrossRefPubMedGoogle Scholar
  34. 34.
    Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8, e82241.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.State Key Laboratory of Oncology in South China, Department of Pathology, Collaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouChina
  2. 2.Department of Molecular OncologyH. Lee Moffitt Cancer Center & Research InstituteTampaUSA
  3. 3.Department of Biological ScienceUniversity of IllinoisChicagoUSA
  4. 4.Department of EndoscopySun Yat-sen University Cancer CenterGuangzhouChina
  5. 5.State Key Laboratory of Oncology in South China, Department of Gastric and Pancreatic Surgery, Collaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouChina

Personalised recommendations